“PROGRESS LIES NOT IN ENHANCING WHAT IS, BUT IN ADVANCING TOWARDS WHAT WILL BE.”
-Khalil Gilbran
We believe this generation deserves next-generation treatments, where survivorship is measured in decades, not months.
MILESTONES
SEPTEMBER 2019
Lucy was diagnosed with metastatic Ewing Sarcoma & began a 40-year-old treatment protocol, containing the most toxic chemo on the market.
APRIL 2020
The Little Warrior Foundation was formed on hospital WiFi. Originally “The Spada Pediatric Sarcoma Foundation” – what a mouthful!
AUGUST 2020
Lucy finishes her treatment: 14 rounds of chemo and 43 rounds of radiation, with 30 blood transfusions required to survive the aggressive treatment.
SEPTEMBER 2020
The foundation issues the first grant: $150,000 to cc-TDI for research and laboratory testing of investigational maintenance therapies
APRIL 2021
$165,000 granted to Dr. Sholler and Beat Childhood Cancer Foundation for precision medicine in a relapsed setting and a molecular tumor board. Learn More »
April 2021
$100,000 granted to Cleveland Clinic (Pete Anderson, MD, PhD and Erin Murphy, MD) to investigate SBRT radiation as a form of local control in hard-to-resect locations. Learn More »
June 2021
$55,00 grant to Georgetown University (Aykut Üren, MD) to kick off a collaborative effort to find a Ewing Protein Degrader.
DECEMBER 2021
Granted $200,000 to Cleveland Clinic (Timothy Chan MD, PhD) for ImmunoOncology research and treatment development leveraging mRNA vaccine technology.
JANUARY 2022
Granted $150,000 to Memorial Sloan Kettering (Emily Slotkin, MD) for a clinical trial combining LY2880070 and gemcitabine to treat relapsed patients.
DECEMBER 2022
Granted $250,000 granted to Dr. Sholler & Beat Childhood Cancer for the continuation of the IN:Formation precision medicine program.
Learn More »
AUGUST 2022
Committed $150,000 to Cleveland Clinic
(Pete Anderson, MD) for Clinical Trial design and
Pre-Trial management.
FEBRUARY 2024
Committed $130,000 to the University of Virginia (John Bushweller, PhD.) for continued development of a small-molecule auto-inhibitor.
Learn More »
DECEMBER 2024
Committed $500,000 to Aptadel Therapeutics (Spain) for continued development of ADEL-101, an aptamer-based drug conjugate targeting the EWS::FLI1 fusion.
Learn More »
FEBRUARY 2025
Committed $100,000 to Dana-Farber Cancer Institute (Dr. Brian Crompton) for the creation of a reproducible, standardized ctDNA assay that can serve as a critical diagnostic and monitoring tool for many pediatric sarcomas..
SEPTEMBER 2024
Granted $350,000 to Dr. Sholler, Penn State Health, and Beat Childhood Cancer for the initiation of three clinical trials.
Learn More »
“We can’t do the research that is needed to move forward without the support of foundations like Little Warrior.
It’s not right, but it’s necessary.”
Emily Slotkin, MD | Memorial Sloan Kettering
AFFILIATED RESEARCH
Cleveland Clinic Foundation | Routine EWS Fusion Analysis in the Oncology Clinic to Identify Cancer-Specific Peptide Sequence Patterns That Span Breakpoints in Ewing Sarcoma and DSRCT
Childhood Cancer Treatment Development Institute | Non-chemotherapy adjuvant agents in TP53 mutant Ewing sarcoma
Ramon Sun, PhD | In situ mass spectrometry imaging reveals heterogeneous glycogen stores in human normal and cancerous tissues
Beat Childhood Cancer - AACR 2022 Abstract | Targeting Ewing sarcoma based on RNA expression
Beat Childhood Cancer - CTOS 2022 Poster | (P 246) Panobinostat Decreases DNA Damage Repair and Increased Sensitivity to Chemotherapy in Ewing Sarcoma
Beat Childhood Cancer - AACR 2023 Abstract | HDAC inhibition increases Ewing sarcoma sensitivity to chemotherapy
Beat Childhood Cancer - CTOS 2023 Poster | Romidepsin Decreases DNA Damage and Repair and Increased Sensitivity to Chemotherapy in Ewing Sarcoma
Levine Cancer Institute | Panobinostat Synergizes with Chemotherapeutic Agents and Improves Efficacy of Standard-of-Care Chemotherapy Combinations in Ewing Sarcoma Cells